Company news: Genzyme, Genentech and more

Share this article:
The FDA has sent a Refuse to File letter to Genzyme over its experimental MS drug Lemtrada (alemtuzumab). The Sanofi subsidiary said in a statement that the FDA has not asked for new studies, but wants the company to make it easier to navigate supporting data. The company said it expects to be able to quickly resubmit its application. The letter comes days after it was reported that Genzyme was changing the distribution of its sister drug Campath, which is indicated for leukemia.

The Centers for Medicare and Medicaid Services issued a one-year reprieve from implementing ICD-10 codes. The change means hospitals will not have to have the new procedures and diagnosis labels in place until October 1, 2014, instead of October 1, 2013. Information Week reported that medical professionals needed a delay, and cited a study that found only 30% of health plans said they would be able to meet at 2013 target date, compared to 61% who said they would definitely be ready by 2014.

Genentech announced Sunday that Phase III trials of breast cancer drug trastuzumab emtansine (T-DM1) significantly extended the lives of patients with HER2-positive metastic breast cancer, compared to patients taking a mix of lapatinib and Xeloda (capecitabine). The study was among patients who had previously undergone Herceptin (trastuzumab) and taxane therapy. Genentech said it has already submitted a biologics license application with the FDA and will soon be filing an authorization application with European regulators.

The Annals of Internal Medicine now has an  iPad app. The free app includes current issues and articles, specialty topic collections, videos and audio summaries, CME quizzes and the ability to search the archives.
Share this article:
You must be a registered member of MMM to post a comment.

Email Newsletters

MM&M Future Leaders


Register now

Early bird $1,950 before 31 October 2014

*Group discounts available on request 

MM&M EBOOK: PATIENT ACCESS

Patient access to pharmaceuticals is a tale of two worlds—affordability has improved for the majority, while the minority is hampered by cost, distribution and red tape. To provide marketers with a well-rounded perspective, MM&M presents this e-book chock full of key insights. Click here to access it.

More in Business Briefs

Genentech shift could prove costly for hospitals

Genentech will use specialty distributors rather than wholesalers, hospitals pharmacy directors have learned.

Novartis said to be stepping out of HCV

Novartis is said to have relinquished rights to an investigational hep. C treatment, signaling its exit from the therapeutic space, according to a former partner's announcement.

Monday Moves: September 15

Hires and promotions for manufacturers, regulatory and agencies